By all appearances, the FDA just decided to use one of MoCRA’s sharpest tools—and sooner than expected.
On December 18, 2025, the U.S. Food and Drug Administration (FDA) quietly (but significantly) released a draft guidance titled “Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry.” The document clarifies how the Agency intends to exercise its mandatory recall authority under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA)—a power the FDA historically did not have.
For cosmetic manufacturers, distributors, packers, and private-label brand owners, this is more than light reading. It’s an early look at how FDA plans to enforce one of MoCRA’s most consequential—and disruptive—provisions in real-world practice.
Why This Is a Big Deal (and Why the Timing Is Curious)
Before MoCRA, FDA could request a cosmetic recall, but it could not order one. Recalls lived squarely in the “voluntary” world under 21 C.F.R. Part 7, relying on industry cooperation and goodwill. MoCRA changed that.
FDA now has explicit authority to mandate Class I recalls of cosmetic products when it determines there is a reasonable probability that a product is:
- Adulterated or misbranded, and
- Likely to cause serious adverse health consequences or death (SAHCOD)
That’s the same high-stakes standard used for the most serious FDA recalls across regulated products.
What makes this guidance particularly noteworthy is the timing. MoCRA passed in December 2022, and FDA has since missed nearly every statutory deadline, including those for:
- Fragrance allergen disclosure rules
- Cosmetic good manufacturing practices (GMPs)
- Talc asbestos testing requirements
Against that backdrop, FDA’s decision to prioritize guidance on mandatory recalls—something MoCRA did not even require FDA to issue guidance on—came as a surprise.
Translation: when FDA shows up early, it’s worth paying attention.
What the Draft Guidance Actually Says
Structured in FDA’s familiar Q&A format, the draft guidance outlines the Agency’s current thinking on how mandatory cosmetic recalls will work in practice. While not legally binding, guidances often function as the FDA’s enforcement playbook—and courts, inspectors, and compliance officers know it.
Key takeaways include:
- When FDA Will Order a Mandatory Recall
The guidance explains the circumstances under which FDA may conclude a recall is necessary, emphasizing serious adverse health risks, including:
- Chemical burns
- Infections
- Other patient safety signals
Notably, adverse events for cosmetics are defined differently than for drugs, and the guidance does little to clarify the boundaries of that expanded definition. This ambiguity leaves room for interpretation—and enforcement discretion.
- The Recall Process (Voluntary First, Mandatory Second)
FDA makes clear that it will generally:
- Give responsible parties the opportunity to voluntarily stop distribution and initiate a recall, and
- Escalate to a mandatory recall order if voluntary actions are deemed insufficient
This mirrors FDA’s approach in other regulated product categories—but now carries real teeth for cosmetics.
- What FDA Expects from Industry
The guidance outlines expectations for:
- Timely communication with FDA
- Public notification and recall effectiveness
- Ongoing cooperation throughout the recall lifecycle
In other words, once FDA pulls the recall lever, it expects companies to move quickly, transparently, and in lockstep with the Agency.
What This Means for the Regulated Cosmetics Industry
For cosmetic companies and compliance teams, this guidance should trigger more than casual interest.
Recall Readiness Is No Longer Optional
With mandatory recall authority now operational, companies should:
- Ensure a Recall Plan is in place
- Review and update recall SOPs
- Ensure rapid product traceability
- Train internal teams on recall execution
- Monitor safety signals more aggressively
Hope is not a recall strategy and documentation will make or break you. FDA inspectors’ favorite phrase remains undefeated: “If it isn’t documented, it didn’t happen.”
Companies should maintain:
- Consistent internal safety assessments
- Robust adverse event reporting systems
- Clear decision-making records
In a recall scenario, documentation is often the difference between cooperation and enforcement escalation.
This Is Your Chance to Influence FDA
Because the guidance is still in draft form, FDA is—at least for now—listening. Stakeholders have a meaningful opportunity to weigh in on key issues, including lingering ambiguities around what qualifies as a “serious adverse event,” the practical realities of recall timelines, and the downstream impact recalls can have on supply chains and retail partners. While FDA guidance documents technically remain open for comment indefinitely, the Agency has made clear that submissions received by February 17, 2026 are far more likely to influence the final version. In regulatory terms: speak now, or forever hold your peace.
What Comes Next?
FDA’s Office of Cosmetics and Colors has already been reshuffled—moving from the Human Foods Program to the Office of the Chief Scientist—yet MoCRA implementation has remained sluggish.
The release of this draft guidance could signal:
- A renewed enforcement posture
- A shift toward action over rulemaking
- Or simply FDA choosing to flex where it already has authority
FDA’s draft guidance on mandatory cosmetic recalls is a wake-up call wrapped in bureaucratic calm. While MoCRA’s broader rollout has been slow, this move signals that FDA is ready to enforce where it already has power.
Cosmetic companies—especially those operating in highly regulated or high-risk product categories—should treat this guidance as both a compliance roadmap and an invitation to engage.
For more information on this guidance, for assistance with drafting/reviewing a cosmetic recall plan, and for other FDA cosmetic compliance and enforcement questions, please email info@garg-law.com.
